Patents by Inventor Ana Martinez Gil

Ana Martinez Gil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,2-DIHYDROQUINOLINE-2-ONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY
    Publication number: 20240277692
    Abstract: The present invention relates to 1,2-dihydroquinoline-2-ones of formula (I): or a pharmaceutically acceptable salt or solvate thereof, for its use in the treatment of limb girdle muscular dystrophy.
    Type: Application
    Filed: May 23, 2022
    Publication date: August 22, 2024
    Inventors: Ana MARTÍNEZ GIL, Valle PALOMO RUIZ, Miren Ametsa SÁENZ PEÑA, Adolfo José LÓPEZ DE MUNAIN ARREGI
  • THIADIAZOLIDINONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY
    Publication number: 20240245657
    Abstract: The present invention relates to 2,4-disubstituted thiadiazolidinones of formula (I): or a pharmaceutically acceptable salt or solvate thereof, for its use in the treatment of limb girdle muscular dystrophy.
    Type: Application
    Filed: May 23, 2022
    Publication date: July 25, 2024
    Inventors: Ana MARTÍNEZ GIL, Valle PALOMO RUIZ, Miren Ametsa SÁENZ PEÑA, Adolfo José LÓPEZ DE MUNAIN ARREGI
  • LRRK2 inhibiting compounds and use thereof for treating neurodegenerative diseases
    Patent number: 11912678
    Abstract: The present invention relates to a series of compounds having a structural benzothiazole-benzamide core with capacity to inhibit the LRRK2 enzyme, due to which the invention also relates to the use of these compounds for treating neurodegenerative diseases in which this enzyme is involved, such as Parkinson's Disease or Alzheimer's Disease.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: February 27, 2024
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS
    Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Josefa Zaldivar Diaz De Bonilla, Rocio Benitez Fernandez
  • MAMMAL KINASE INHIBITORS TO PROMOTE IN VITRO EMBRYOGENESIS INDUCTION OF PLANTS
    Publication number: 20230025843
    Abstract: The present invention relates to the use of mammal kinase inhibitors, preferably human kinase inhibitors, to promote the induction of in vitro embryogenesis, a strategy never used in plants systems before. The results obtained indicated that these inhibitors have beneficial effects in both crop and forest plants in in vitro systems of microspore and somatic embryogenesis.
    Type: Application
    Filed: November 25, 2020
    Publication date: January 26, 2023
    Inventors: Pilar SÁNCHEZ TESTILLANO, Ana MARTINEZ GIL, Carmen GIL AYUSO-GONTAN, Eduardo BERENGUER PEINADO, Elena CARNEROS GARCÍA, Yolanda PÉREZ PÉREZ
  • CDC-7-inhibitor compounds and use thereof for the treatment of neurological conditions
    Patent number: 11446304
    Abstract: The present invention relates to a series of substituted purine derivatives capable of inhibiting CDC7 kinase activity and, as such, suitable for use in the treatment of neurological diseases such as, inter alia, Alzheimer's disease, amyotrophic lateral sclerosis or frontotemporal dementia, involving hyperphosphorylation of TDP-43 and the subsequent formation of aggregates, induced by CDC7.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: September 20, 2022
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC)
    Inventors: Ana Martinez Gil, Daniel I. Perez, Carmen Gil Ayuso-Gontán, Angeles Martin-Requero, Elisa Rojas Prats, Loreto Martinez-Gonzalez, Concepción Perez
  • CDC7-Inhibiting Purine Derivatives and their use for the Treatment of Neurological Conditions
    Publication number: 20210346388
    Abstract: The present invention relates to the use of a series of purine derivatives having the following general formula: (I) and which are capable of inhibiting CDC7 kinase activity and, therefore, suitable for use in the treatment of neurological diseases such as, inter alia, Alzheimer's disease, amyotrophic lateral sclerosis or frontotemporal dementia, which involve hyperphosphorylation of TDP-43 and the subsequent formation of clusters, induced by CDC7.
    Type: Application
    Filed: September 23, 2019
    Publication date: November 11, 2021
    Inventors: Ana MARTINEZ GIL, Carmen GIL AYUSO-GONTAN, Angeles MARTIN REQUERO, Elisa ROJAS PRATS, Loreto MARTINEZ-GONZALEZ
  • LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES
    Publication number: 20210323936
    Abstract: The present invention relates to a series of compounds having a structural benzothiazole-benzamide core with capacity to inhibit the LRRK2 enzyme, due to which the invention also relates to the use of these compounds for treating neurodegenerative diseases in which this enzyme is involved, such as Parkinson's Disease or Alzheimer's Disease.
    Type: Application
    Filed: August 8, 2019
    Publication date: October 21, 2021
    Inventors: Ana MARTINEZ GIL, Carmen GIL AYUSO-GONTAN, Josefa ZALDIVAR DIAZ DE BONILLA, Rocio BENITEZ FERNANDEZ
  • CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS
    Publication number: 20200093828
    Abstract: The present invention relates to a series of substituted purine derivatives capable of inhibiting CDC7 kinase activity and, as such, suitable for use in the treatment of neurological diseases such as, inter alia, Alzheimer's disease, amyotrophic lateral sclerosis or frontotemporal dementia, involving hyperphosphorylation of TDP-43 and the subsequent formation of aggregates, induced by CDC7.
    Type: Application
    Filed: March 21, 2018
    Publication date: March 26, 2020
    Inventors: Ana MARTINEZ GIL, Daniel PEREZ, Carmen GIL AYUSO-GONTÁN, Angeles MARTIN-REQUERO, Elisa ROJAS PRATS, Loreto MARTINEZ-GONZALEZ, Concepción PEREZ
  • AMINOPHENOTHIAZINES FOR MODULATING THE NUMBER OF SYNAPSES
    Publication number: 20190076439
    Abstract: The present invention relates to the use of a group of compounds with a phenothiazine core with the following general formula (I): for treating diseases of the central nervous system which present abnormalities in the synapse such as autism or Fragile X syndrome. The compounds of the invention are involved in the interaction of the NCS1 and Ric8 proteins involved in the synaptogenesis process.
    Type: Application
    Filed: September 19, 2016
    Publication date: March 14, 2019
    Inventors: Ana MARTÍNEZ GIL, Carmen GIL AYUSO-GONTAN, Nuria CAMPILLO MARTÍN, Maria José SANCHEZ BARRENA, Alicia MANSILLA APARICIO, Alberto FERRÚS GAMERO
  • S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by PDE7
    Patent number: 9796687
    Abstract: The present invention relates to a family of S-substituted quinazoline derivatives that inhibitors of the enzyme phosphodiesterase 7 (PDE7), useful for the treatment or prevention of diseases mediated by said enzyme, especially inflammatory, neurodegenerative, neurological, psychiatric and/or autoimmune diseases.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: October 24, 2017
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
    Inventors: Ana Martinez Gil, Carmen Belen Gil Ayuso-Gontan, Daniel Ignacio Perez Fernandez, Ana Maria Garcia Fernandez
  • Heterocyclic GSK-3 allosteric modulators
    Patent number: 9757369
    Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: September 12, 2017
    Assignee: Consejo Superior de Investigaciones Cientificas (CSIC)
    Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez
  • Heterocyclic GSK-3 Allosteric Modulators
    Publication number: 20170196850
    Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
    Type: Application
    Filed: January 25, 2017
    Publication date: July 13, 2017
    Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez
  • Substituted 5-imino-1,2,4-thiadiazoles that can be used to treat neurodegenerative diseases
    Patent number: 9604947
    Abstract: The present invention is based on the use of a broad family of 5-imino-1,2,4-thiadiazoles as potential new drugs for the treatment of diseases in which PDE7 inhibition is important, specially inflammatory diseases, autoimmune and neurodegenerative disorders. On the other hand, compounds of the 5-imino-1,2,4-thiadiazole family are here described, as well as their synthetic procedures, and they may have great application as drug or drug candidates.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: March 28, 2017
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
    Inventors: Ana Martínez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Daniel Perez Fernandez, Concepción Perez Martín, Ana María Perez Castillo, María Isabel Loza Garcia, María Isabel Cadavid Torres, José Brea Floriani
  • Substituted benzothiazoles and therapeutic uses thereof for the treatment of human diseases
    Patent number: 9592224
    Abstract: The invention relates to a family of differently substituted benzothiazoles having inhibitory activity against casein kinase 1 (CK-1) enzyme, as a result of which they are suitable for use in the treatment or prevention of diseases caused by this enzyme, particularly diseases associated with circadian rhythm and inflammatory, autoimmune, psychiatric, neurodegenerative, neurological or ophthalmic diseases, as well as for inducing cell regeneration
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: March 14, 2017
    Assignee: DONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC)
    Inventors: Ana Martínez Gil, Daniel Ignacio Pérez Fernández, Carmen Gil Ayuso-Gontán, Irene García Salado, Miriam Redondo Sancho, Concepción Pérez Martínez
  • Heterocyclic GSK-3 allosteric modulators
    Patent number: 9585879
    Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: March 7, 2017
    Assignee: Consejo Superior de Investigaciones Cientificas (CSIC)
    Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez
  • S-SUBSTITUTED QUINAZOLINES AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF DISEASES MEDIATED BY PDE7
    Publication number: 20160340320
    Abstract: The present invention relates to a family of S-substituted quinazoline derivatives that inhibitors of the enzyme phosphodiesterase 7 (PDE7), useful for the treatment or prevention of diseases mediated by said enzyme, especially inflammatory, neurodegenerative, neurological, psychiatric and/or autoimmune diseases.
    Type: Application
    Filed: May 17, 2016
    Publication date: November 24, 2016
    Inventors: Ana Martinez Gil, Carmen Belen Gil Ayuso-Gontan, Daniel Ignacio Perez Fernandez, Ana Maria Garcia Fernandez
  • Heterocyclic GSK-3 Allosteric Modulators
    Publication number: 20160113918
    Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
    Type: Application
    Filed: October 22, 2015
    Publication date: April 28, 2016
    Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez
  • SUBSTITUTED BENZOTHIAZOLES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF HUMAN DISEASES
    Publication number: 20150352082
    Abstract: The invention relates to a family of differently substituted benzothiazoles having inhibitory activity against casein kinase 1 (CK-1) enzyme, as a result of which they are suitable for use in the treatment or prevention of diseases caused by this enzyme, particularly diseases associated with circadian rhythm and inflammatory, autoimmune, psychiatric, neurodegenerative, neurological or ophthalmic diseases, as well as for inducing cell regeneration
    Type: Application
    Filed: December 12, 2013
    Publication date: December 10, 2015
    Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS
    Inventors: Ana MARTÍNEZ GIL, Daniel Ignacio PÉREZ FERNÁNDEZ, Carmen GIL AYUSO-GONTÁN, Irene GARCÍA SALADO, Miriam REDONDO SANCHO, Concepción PÉREZ MARTÍNEZ
  • Use of quinazoline derivatives for neurodegenerative diseases
    Patent number: 9192610
    Abstract: The present invention relates to the use of a series of quinazoline-derived compounds to produce a medicament for the treatment and/or prevention of neurological and/or neurodegenerative diseases, such as Parkinson's disease or Alzheimer's disease. The present invention also relates to a method for the treatment and/prevention of neurological and/neurodegenerative diseases comprising the administration of a therapeutically effective amount of said compounds.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: November 24, 2015
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
    Inventors: Ana Martínez Gil, Carmen Gil Ayuso-Gontan, Concepción Pérez Martín, Ana Pérez Castillo, José Morales García, Miriam Redondo Sancho, Marina Sanz San Cristóbal
  • Heterocyclic GSK-3 allosteric modulators
    Patent number: 9193688
    Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: November 24, 2015
    Assignee: Consejo Superior de Investigaciones Cientificas
    Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez